2019 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience
*Purpose: Post-transplant lymphoproliferative disorders (PTLD) is relatively rare but the most common, life-threatening neoplasms after organ transplantation. Because of their heterogeneity from benign to malignant…2019 American Transplant Congress
Post-transplant Lymphoproliferative Disorder Following Intestine Transplantation: Contemporary Single Center Experience
Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC
*Purpose: The purpose of this study was to examine the characteristics and risk factors for PTLD after intestinal transplant.*Methods: Retrospective review of intestinal transplant recipients…2019 American Transplant Congress
EBV+ PTLD in the Modern Immunosuppression Era: Role of EBV Serology and DNAemia-Preliminary Data from CTOT-C06
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is an…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…2019 American Transplant Congress
Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1)
*Purpose: Malignancies attributable to EBV, such as post-transplant lymphoproliferative disorder (PTLD), represent 1.8% of global cancer deaths. PTLD occurs in 1-20% of transplant recipients and…2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
1UHN, Toronto, ON, Canada, 2SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…2019 American Transplant Congress
Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) can manifest as a B-cell malignancy associated with Epstein-Barr virus (EBV) infection. Risk of PTLD is greatest in EBV D+/R-…2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…2019 American Transplant Congress
Phylogenetic Analysis of the Epstein Barr Virus Nuclear Antigen-1 and Associated Correlates among Canadian Transplant Patients
*Purpose: The effect of the genetic diversity of the Epstein-Barr virus (EBV) on clinical outcomes in the transplant setting is important to study. We examined…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »